Accelerating transition into a ‘therapeutic platform company’ as accumulated investment reaches KRW 170 billion
[by Kang, In Hyo] 무료 바카라 게임dit, a company specializing in the development of 무료 바카라 게임 therapies, has successfully secured USD 25 million (approximately KRW 36 billion) in funding, thereby accelerating the clinical advancement of its proprietary pipeline programs.
GenEdit announced on February 26 that it successfully completed a pre-IPO financing totaling USD 25 million. This funding will be allocated to accelerate the advancement of its proprietary gene delivery platform, ‘NanoGalaxy,’ and further transition into a therapeutic platform company.
The pre-IPO round was completed ahead of schedule and was fully subscribed by existing investors. Existing investor Yuanta Investment served as the lead investor. Participating investors included Loftirock Investment, Dayli Partners, DSC Investment, SV Investment, Pathway Investment, Woori Venture Partners, Korea Investment Partners, Kiwoom Investment, and Sequoia Capital.
With the completion of this pre-IPO funding, GenEdit has secured additional capital to support the clinical advancement of its proprietary pipeline and the continued expansion of its NanoGalaxy platform. As a result, the company’s total accumulated funding has reached USD 120 million (approximately KRW 170 billion).
"Having secured the technological capability to deliver gene therapies to the appropriate target cells, we are now developing treatments that can generate real change for patients. We are transitioning from a delivery platform company to a higher value-added 'therapeutic platform company'. This financing will accelerate the clinical initiation of our first proprietary program and support the continued expansion of NanoGalaxy's application scope," said Ryan Lee, CEO of GeneEdit.
"GeneEdit is setting a next-generation benchmark by addressing one of the biggest challenges in gene therapy, 'targeted delivery,' through its proprietary NanoGalaxy platform. Notably, the company has already proven its commercial value and technological reliability through equity investments and licensing agreements with major global pharmaceutical companies," said Vincent Jeong, CEO of Yuanta Investment. "GeneEdit's forthcoming clinical trials in autoimmune disease treatments, as well as its expansion into the in vivo CAR-T field, are expected to serve as a turning point in its evolution into a globally competitive novel drug development company."
"As the manager of the Ministry of Health and Welfare's 'K-Bio Vaccine Fund No. 1' and the lead investor in this round, Yuanta Investment is confident that GeneEdit will emerge as a game changer in the global gene therapy market. We intend to continue fully supporting GeneEdit's new drug development efforts both in the lead-up to its listing and in the post-listing phase," Jeong emphasized.
Meanwhile, following the completion of the pre-IPO investment, 무료 바카라 게임Edit officially changed its corporate name to BreezeBio, reflecting its vision of embodying the hope of 무료 바카라 게임 therapy.
GeneEdit entered into a joint research and licensing agreement in 2024 with Genentech, a global pharmaceutical company under the Roche Group, to advance the development of therapeutics for autoimmune diseases. The company emphasized that this collaboration demonstrates the global competitiveness of its core gene delivery technology, the ‘NanoGalaxy’ platform.
NanoGalaxy is a platform engineered to enable tissue-selective delivery of gene therapies through the application of artificial intelligence (AI). The technology is based on non-viral, non-lipid nanoparticle systems and is characterized by its unique characteristic of facilitating ‘personalized treatment.’
무료 바카라 게임Edit is a biotechnology venture co-founded in 2016 by Ryan Lee, who holds a Ph.D. in bioengineering from University of California Berkeley (UC Berkeley), and Chief Operating Officer Huey Park. Based in San Francisco, the two founders established the company in Silicon Valley to develop therapeutics leveraging precision 무료 바카라 게임 delivery technologies. Their efforts build upon prior collaborative research on 무료 바카라 게임 editing delivery systems conducted by Nobel laureate Professor Jennifer Doudna.
무료 바카라 게임Edit has experienced rapid growth since its founding, securing support from global investors such as Sequoia Capital, Bow Capital, and DCVC Bio. Notably, the multinational pharmaceutical company Eli Lilly and Company participated in the company's two prior funding rounds and played a pivotal role in expanding 무료 바카라 게임Edit's global partnership network.